Cargando…

Gut microbiota: A new therapeutic target for diabetic cardiomyopathy

Diabetic cardiomyopathy seriously affects quality of life and even threatens life safety of patients. The pathogenesis of diabetic cardiomyopathy is complex and multifactorial, and it is widely accepted that its mechanisms include oxidative stress, inflammation, insulin resistance, apoptosis, and au...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Suxin, Cai, Zhengyao, Luan, Xingzhao, Wang, Haibo, Zhong, Yi, Deng, Li, Feng, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461091/ https://www.ncbi.nlm.nih.gov/pubmed/36091756 http://dx.doi.org/10.3389/fphar.2022.963672

Ejemplares similares

Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy
por: Cai, Zhengyao, et al.
Publicado: (2022)

Amelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein–Coupled Receptor 5
por: Cai, Zhengyao, et al.
Publicado: (2021)

Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
por: Zhuang, Tongxi, et al.
Publicado: (2021)

Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice
por: Yang, Yang, et al.
Publicado: (2021)

Resveratrol Modulates the Gut Microbiota and Inflammation to Protect Against Diabetic Nephropathy in Mice
por: Cai, Ting-Ting, et al.
Publicado: (2020)

Gut microbiota-derived metabolites in inflammatory diseases based on targeted metabolomics
por: Xu, Hui, et al.
Publicado: (2022)

Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy
por: Sun, Huiyan, et al.
Publicado: (2023)

The Role of Gut Microbiota and Microbiota-Related Serum Metabolites in the Progression of Diabetic Kidney Disease
por: Zhang, Qing, et al.
Publicado: (2021)

The regulatory effects of second-generation antipsychotics on lipid metabolism: Potential mechanisms mediated by the gut microbiota and therapeutic implications
por: Chen, Hui, et al.
Publicado: (2023)

Characteristics of Serum Metabolites and Gut Microbiota in Diabetic Kidney Disease
por: Zhang, Bo, et al.
Publicado: (2022)

Herbal Medicine, Gut Microbiota, and COVID-19
por: Chen, Ziqi, et al.
Publicado: (2021)

The Role of Gut Microbiota—Gut—Brain Axis in Perioperative Neurocognitive Dysfunction
por: Lu, Jian, et al.
Publicado: (2022)

Regulating Gut Microbiome: Therapeutic Strategy for Rheumatoid Arthritis During Pregnancy and Lactation
por: Yao, Yao, et al.
Publicado: (2020)

Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target
por: Yang, Shengjie, et al.
Publicado: (2019)

Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
por: Cruz, Clênio Silva, et al.
Publicado: (2021)

Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease
por: Wang, Xueliang, et al.
Publicado: (2022)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
por: Luan, Yi, et al.
Publicado: (2022)

CaMKII Inhibition is a Novel Therapeutic Strategy to Prevent Diabetic Cardiomyopathy
por: Veitch, Christopher R., et al.
Publicado: (2021)

Cordyceps militaris extracts and cordycepin ameliorate type 2 diabetes mellitus by modulating the gut microbiota and metabolites
por: Liu, Xinyuan, et al.
Publicado: (2023)

NSAID–Gut Microbiota Interactions
por: Maseda, Damian, et al.
Publicado: (2020)

Gut Microbiota: A Novel Regulator of Cardiovascular Disease and Key Factor in the Therapeutic Effects of Flavonoids
por: Li, Qinyu, et al.
Publicado: (2021)

Epigenetics and Beyond: Targeting Histone Methylation to Treat Type 2 Diabetes Mellitus
por: Yang, Yang, et al.
Publicado: (2022)

Bear bile powder ameliorates type 2 diabetes via modulation of metabolic profiles, gut microbiota, and metabolites
por: Chen, Xing-Ling, et al.
Publicado: (2023)

Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease
por: Wang, Mengdi, et al.
Publicado: (2022)

The modulation of gut microbiota by herbal medicine to alleviate diabetic kidney disease – A review
por: Du, Jinxin, et al.
Publicado: (2022)

Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus
por: Gao, Ruolin, et al.
Publicado: (2022)

Targeting gut microbiota and immune crosstalk: potential mechanisms of natural products in the treatment of atherosclerosis
por: Jing, Jinpeng, et al.
Publicado: (2023)

Gut Microbiota, Short-Chain Fatty Acids, and Herbal Medicines
por: Feng, Wuwen, et al.
Publicado: (2018)

Chocolate, gut microbiota, and human health
por: Hayek, Nabil
Publicado: (2013)

The Role of Gut Microbiota in Atherosclerosis and Hypertension
por: Ma, Junli, et al.
Publicado: (2018)

Gut Microbiota-Based Pharmacokinetics and the Antidepressant Mechanism of Paeoniflorin
por: Yu, Jin-Bo, et al.
Publicado: (2019)

Zi Shen Wan Fang Attenuates Neuroinflammation and Cognitive Function Via Remodeling the Gut Microbiota in Diabetes-Induced Cognitive Impairment Mice
por: Shi, Jiangwei, et al.
Publicado: (2022)

The Effects of Erchen Decoction on Gut Microbiota and Lipid Metabolism Disorders in Zucker Diabetic Fatty Rats
por: Zhao, Tian, et al.
Publicado: (2021)

New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer
por: Lu, Lu, et al.
Publicado: (2022)

Natural products from plants and microorganisms: Novel therapeutics for chronic kidney disease via gut microbiota regulation
por: Zheng, Lin, et al.
Publicado: (2023)

Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration
por: Feng, Ru, et al.
Publicado: (2018)

Investigating the role of NPR1 in dilated cardiomyopathy and its potential as a therapeutic target for glucocorticoid therapy
por: Huang, Yaomeng, et al.
Publicado: (2023)

Understanding the Gut-Kidney Axis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: An Analysis of Gut Microbiota Composition
por: Yu, Meilian, et al.
Publicado: (2022)

Glucosamine Ameliorates Symptoms of High-Fat Diet-Fed Mice by Reversing Imbalanced Gut Microbiota
por: Yuan, Xubing, et al.
Publicado: (2021)

Microbiota and Colorectal Cancer: From Gut to Bedside
por: Silva, Miguel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_njc63rnmvb8qh670t8c92cvtmj